AIM IMMUNOTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.403 USD | +3.33% |
|
+0.75% | -8.39% |
| 16/05 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 | |
| 29/04 | AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 113K 9.44M | Sales 2025 * | 1.78M 148M | Capitalization | 20.51M 1.71B |
|---|---|---|---|---|---|
| Net income 2024 * | -24M -2B | Net income 2025 * | -25M -2.08B | EV / Sales 2024 * | 181 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 11.5 x |
| P/E ratio 2024 * |
-0.82
x | P/E ratio 2025 * |
-0.89
x | Employees | 27 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91% |
More Fundamentals
* Assessed data
More news
Latest transcript on AIM ImmunoTech Inc.
More press releases
More news
| 1 day | +3.33% | ||
| 1 week | +0.75% | ||
| Current month | -1.35% | ||
| 1 month | -15.28% | ||
| 3 months | +6.33% | ||
| 6 months | -10.24% | ||
| Current year | -8.39% |
1 week
0.36
0.43
1 month
0.360.50
Current year
0.320.62
1 year
0.320.75
3 years
0.292.40
5 years
0.297.50
10 years
0.29211.20
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 17/08/17 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 04/22/04 |
| Chief Tech/Sci/R&D Officer | - | 01/22/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 28/23/28 |
William Mitchell
CHM | Chairman | 89 | 01/98/01 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 17/08/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 0.403 | +3.33% | 274,617 |
| 16/24/16 | 0.39 | -2.40% | 287,138 |
| 15/24/15 | 0.3996 | +3.95% | 178,351 |
| 14/24/14 | 0.3844 | -9.32% | 499,297 |
| 13/24/13 | 0.4239 | +5.97% | 114,425 |
Delayed Quote Nyse, May 18, 2024 at 01:30 am IST
More quotes
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Calendar
13/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.403
USD
Average target price
3.5
USD
Spread / Average Target
+768.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.39% | 19.85M | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- AIM Stock
